Investor Home

Corporate Profile

Cerecor Inc. is a clinical stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric diseases by addressing the unmet medical needs of underserved patient segments. We are committed to the development of drugs that improve lives by applying our extensive knowledge and experience in central nervous system disorders....more

Recent Newsmore 
09/21/16
Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder
Top-Line Data Now Expected in November 2016 BALTIMORE--(BUSINESS WIRE)--Sep. 21, 2016-- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has completed patient enrollment in its Phase 2 clinical trial for CERC-301, Clin301-203, as an oral, rapidly acting adjunctive treatment of major dep... 
09/12/16
Cerecor Enters Into a $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
BALTIMORE--(BUSINESS WIRE)--Sep. 12, 2016-- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has entered into a $15 million common stock purchase agreement (the “Agreement”) and a registration rights agreement with Aspire Capital Fund, LLC (“Aspire”), a Chicago-based institutional investor. ... 
09/06/16
Cerecor Announces Last Patient Enrolled in Phase 2 Clinical Trial with CERC-501 for Smoking Cessation
Top-Line Phase 2 Data Expected in December 2016 BALTIMORE--(BUSINESS WIRE)--Sep. 6, 2016-- Cerecor Inc. (NASDAQ:CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has completed patient enrollment in its Phase 2 clinical trial for CERC-501, “A Randomized, Double-Blind, Placebo-Controlled, Cross-over Design Study of ... 
Upcoming Eventsmore 
There are currently no events scheduled.
IR Contact

E-mail: ir@cerecor.com

Stock Quotemore 
Exchange :NASDAQ CM (US Dollar)
Price :$4.91
Change : Stock is Up 0.11 (2.29%)
Volume :46,623
Data as of 09/23/16 3:58 p.m. ET
Minimum 15 minute delay
Request Information
 
Obtain investor relations information by contacting us.
 
More
E-mail Alerts
Sign up to receive e-mail alerts whenever Cerecor, Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.